Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16056938 | 0.90 | LMNA (0.51) | LMNAMAPTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL16056939 | 0.90 | LMNA (0.51) | LMNAMAPTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL16083238 | 0.87 | GABRA2 (0.52) | LMNAMAPTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL18157337 | 0.84 | LMNA (0.52) | LMNAMAPTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL18157353 | 0.80 | LMNA (0.48) | LMNAMAPTSMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL16057651 | 0.80 | LMNA (0.48) | LMNAMAPTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL16057763 | 0.79 | ALDH1A1 (0.48) | LMNAMAPTSMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL16056591 | 0.79 | LMNA (0.47) | LMNAMAPTSMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL16056218 | 0.78 | DRD4 (0.39) | LMNAMAPTSMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL9454553 | 0.71 | GABRA2 (0.61) | MAPTSMN1; SMN2ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304499-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | LMNA 961/4885MAPT 3581/4885SMN1; SMN2 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.